

25. (New) The antibody of claim 24, which specifically binds to the polypeptide of amino acids 2 to 342 of SEQ ID NO:2.

26. (New) The antibody of claim 25, which specifically binds to the mature polypeptide produced upon cellular expression of the polypeptide of SEQ ID NO:2.

27. (New) The antibody of claim 23, wherein said antibody is polyclonal.

28. (New) The antibody of claim 23, wherein said antibody is monoclonal.

29. (New) The antibody of claim 28, wherein said antibody is produced by a method selected from the group consisting of the hybridoma technique, the trioma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique.

30. (New) The antibody of claim 29, wherein said antibody is produced by the hybridoma technique.

31. (New) The antibody of claim 29, wherein said antibody is produced by the trioma technique.

32. (New) The antibody of claim 27, wherein said antibody is produced by the human B-cell hybridoma technique.

33. (New) The antibody of claim 29, wherein said antibody is produced by the EBV-hybridoma technique.

34. (New) The antibody of claim 23, wherein said antibody is chimeric.

35. (New) The antibody of claim 23, wherein said antibody is humanized.

36. (New) The antibody of claim 23, wherein said antibody is produced in transgenic mice.

37. (New) The antibody of claim 23, wherein said antibody is a single-chain antibody.

38. (New) A composition comprising the antibody of claim 23, and a carrier.

39. (New) A method of producing the antibody of claim 23, comprising:

- (a) introducing an ~~immunogen~~ into an animal; and
- (b) recovering said antibody.

40. (New) An isolated antibody fragment which specifically binds to the polypeptide of SEQ ID NO:2.

41. (New) The antibody fragment of claim 40, which specifically binds to the polypeptide of amino acids 1 to 342 of SEQ ID NO:2.

42. (New) The antibody fragment of claim 41, which specifically binds to the polypeptide of amino acids 2 to 342 of SEQ ID NO:2.

43. (New) The antibody fragment of claim 42, which specifically binds to the mature polypeptide produced upon cellular expression of the polypeptide of SEQ ID NO:2.

44. (New) The antibody fragment of claim 40, wherein said antibody fragment comprises an Fab fragment.

45. (New) The antibody fragment of claim 40, wherein said antibody fragment comprises a single chain antibody fragment.

46. (New) The antibody fragment of claim 40, wherein said antibody fragment is chimeric.

47. (New) The antibody fragment of claim 40, wherein said antibody fragment is the product of an Fab expression library.

48. (New) The antibody fragment of claim 40, wherein said antibody fragment is fused to a heterologous polypeptide.

49. (New) A composition comprising the antibody fragment of claim 40, and a carrier.

50. (New) A method of producing the antibody fragment of claim 40, comprising:

- (a) introducing an immunogen into an animal; and
- (b) recovering said antibody fragment.

51. (New) An isolated antibody which specifically binds the polypeptide encoded by the human cDNA in ATCC Deposit No. 209003.  
*A1  
cm+*

52. (New) The antibody of claim 51, which specifically binds to the mature polypeptide produced upon cellular expression of the polypeptide encoded by the human cDNA in ATCC Deposit No. 209003.

53. (New) The antibody of claim 51, wherein said antibody is polyclonal.

54. (New) The antibody of claim 51, wherein said antibody is monoclonal.

55. (New) The antibody of claim 54, wherein said antibody is produced by a method selected from the group consisting of the hybridoma technique, the trioma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique.

56. (New) The antibody of claim 55, wherein said antibody is produced by the hybridoma technique.

57. (New) The antibody of claim 55, wherein said antibody is produced by the trioma technique.

58. (New) The antibody of claim 55, wherein said antibody is produced by the human B-cell hybridoma technique.

59. (New) The antibody of claim 55, wherein said antibody is produced by the EBV-hybridoma technique.

60. (New) The antibody of claim 51, wherein said antibody is chimeric.

61. (New) The antibody of claim 51, wherein said antibody is humanized.

62. (New) The antibody of claim 51, wherein said antibody is produced in transgenic mice.

63. (New) The antibody of claim 51, wherein said antibody is a single-chain antibody.

64. (New) A composition comprising the antibody of claim 51, and a carrier.

65. (New) A method of producing the antibody of claim 51, comprising:

- (a) introducing an immunogen into an animal; and
- (b) recovering said antibody fragment.

66. (New) An isolated antibody fragment which specifically binds to the polypeptide encoded by the human cDNA in ATCC Deposit No. 209003.

67. (New) The antibody fragment of claim 66, which specifically binds to the mature polypeptide produced upon cellular expression of the polypeptide encoded by the human cDNA in ATCC Deposit No. 209003.

68. (New) The antibody fragment of claim 66, wherein said antibody fragment comprises an Fab fragment.

69. (New) The antibody fragment of claim 66, wherein said antibody fragment comprises a single chain antibody fragment.

70. (New) The antibody fragment of claim 66, wherein said antibody fragment is chimeric.

71. (New) The antibody fragment of claim 66, wherein said antibody fragment is the product of an Fab expression library.

72. (New) The antibody fragment of claim 66, wherein said antibody fragment is fused to a heterologous polypeptide.

73. (New) A composition comprising the antibody fragment of claim 66, and a carrier.

74. (New) A method of producing the antibody fragment of claim 66, comprising:

- (a) introducing an immunogen into an animal; and
- (b) recovering said antibody fragment.

75. (New) A method to screen for a compound which binds to a polypeptide comprising amino acids 2 to 342 of SEQ ID NO:2, comprising:

- (a) contacting a compound to be screened with said polypeptide; and
- (b) determining if said compound binds to said polypeptide.

76. (New) The method of claim 75, wherein said compound to be screened comprises a molecule selected from the group consisting of a small molecule, a peptide, a peptide-like molecule, a polypeptide, and an antibody.

77. (New) A method to screen for a compound which binds to the polypeptide encoded by the human cDNA in ATCC Deposit No. 209003, comprising:

- (a) contacting a compound to be screened with said polypeptide; and

(b) determining if said compound binds to said polypeptide.

A  
Claimed:

78. (New) The method of claim 77, wherein said compound to be screened comprises a molecule selected from the group consisting of a small molecule, a peptide, a peptide-like molecule, a polypeptide, and an antibody. --

PRINTED IN U.S.A. 00022560